Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.48 |
| ▸ | RXRB | P28702 | 2/20 | 0.48 |
| ▸ | RXRG | P48443 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 4/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.42 |
| ▸ | LTC4S | Q16873 | 6/20 | 0.41 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL236030 | 0.89 | LTC4S (0.49) | RXRARXRBRXRGMAOBNR4A2 | |
| SCHEMBL238157 | 0.79 | MAOB (0.52) | RXRARXRBRXRGMAOBNR4A2 | |
| SCHEMBL239377 | 0.78 | RXRA (0.54) | RXRARXRBRXRGMAOBNR4A2 | |
| SCHEMBL239256 | 0.77 | LTC4S (0.65) | LTC4S | |
| SCHEMBL239257 | 0.76 | P4HTM (0.47) | LTC4SP4HTM | |
| SCHEMBL2755473 | 0.76 | RXRA (0.51) | RXRARXRBRXRGMAOBNR4A2 | |
| SCHEMBL11380057 | 0.74 | P4HTM (0.72) | RXRARXRBRXRGMAOBNR4A2 | |
| SCHEMBL2755493 | 0.74 | LTC4S (0.67) | LTC4S | |
| SCHEMBL2910095 | 0.70 | MAOB (0.69) | RXRARXRBRXRGMAOBNR4A2 | |
| SCHEMBL9988347 | 0.70 | LTC4S (0.41) | LTC4SP4HTM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004244-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2012-01-05 | — | — | US | disclosed |
| US-20120004244-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2012-01-05 | — | — | US | disclosed |
| US-20120004244-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2012-01-05 | — | — | US | disclosed |
| US-20110319431-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2011-12-29 | — | — | US | disclosed |
| US-20110319431-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2011-12-29 | — | — | US | disclosed |
| US-20110319431-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004244-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | LTC4S, LTB4R2, LTB4R | RXRA 2420/4885RXRB 2018/4885RXRG 2906/4885 |
| US-20110319431-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | LTC4S, LTB4R2, LTB4R | RXRA 2238/4885RXRB 1966/4885RXRG 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.